Cargando…
Bevacizumab for the treatment of a complicated posterior melanocytoma
PURPOSE: To present a case of a complicated posterior melanocytoma that was successfully treated with intravitreal bevacizumab. CASE REPORT: A 50-year-old Caucasian man was referred with sudden-onset metamorphopsia and decreased vision in his right eye over the course of the last 2 months. His best-...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358416/ https://www.ncbi.nlm.nih.gov/pubmed/25834382 http://dx.doi.org/10.2147/OPTH.S80152 |
_version_ | 1782361268174192640 |
---|---|
author | Urrets-Zavalia, Julio A Crim, Nicolas Esposito, Evangelina Correa, Leandro Gonzalez-Castellanos, M Eugenia Martinez, Dana |
author_facet | Urrets-Zavalia, Julio A Crim, Nicolas Esposito, Evangelina Correa, Leandro Gonzalez-Castellanos, M Eugenia Martinez, Dana |
author_sort | Urrets-Zavalia, Julio A |
collection | PubMed |
description | PURPOSE: To present a case of a complicated posterior melanocytoma that was successfully treated with intravitreal bevacizumab. CASE REPORT: A 50-year-old Caucasian man was referred with sudden-onset metamorphopsia and decreased vision in his right eye over the course of the last 2 months. His best-corrected visual acuity was 20/80 and poorer than Jaeger 14 in the right eye, and 20/20 and Jaeger 1 in his left eye. In the right fundus, there was a melanocytic lesion occupying the inferotemporal quadrant of the optic disk, extending to the adjacent choroid inferiorly; optic nerve edema, superotemporal retinal vein dilatation, and subretinal fluid under the macula and nasal half of the posterior pole were observed, and a subretinal choroidal neovascularization complex was observed adjacent to the superotemporal margin of the optic disk, confirmed by fluorescein angiography, surrounded by a dense subretinal hemorrhage. Optical coherence tomography showed retinal edema and detachment of neurosensory retina. The patient was treated with three consecutive doses on a monthly basis of intravitreal 1.25 mg/0.05 mL bevacizumab. Visual acuity recovered rapidly, and at 4 months after treatment, it was 20/20 and Jaeger 1, with complete resolution of macular edema and subretinal fluid and hemorrhage. After 3 years of follow-up, best-corrected visual acuity remained stable, macular area was normal, and there was no evident optic nerve edema, retinal vein caliber and aspect were normal, and there was no significant change of the tumor. Fluorescein angiography only evidenced late staining of choroidal neovascularization scar, and optical coherence tomography showed a normal macular anatomy. CONCLUSION: Intravitreal bevacizumab was effective in the treatment of choroidal neovascularization, optic nerve edema, venous dilatation, and local capillary telangiectasia, complicating an optic disk melanocytoma. |
format | Online Article Text |
id | pubmed-4358416 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43584162015-04-01 Bevacizumab for the treatment of a complicated posterior melanocytoma Urrets-Zavalia, Julio A Crim, Nicolas Esposito, Evangelina Correa, Leandro Gonzalez-Castellanos, M Eugenia Martinez, Dana Clin Ophthalmol Case Report PURPOSE: To present a case of a complicated posterior melanocytoma that was successfully treated with intravitreal bevacizumab. CASE REPORT: A 50-year-old Caucasian man was referred with sudden-onset metamorphopsia and decreased vision in his right eye over the course of the last 2 months. His best-corrected visual acuity was 20/80 and poorer than Jaeger 14 in the right eye, and 20/20 and Jaeger 1 in his left eye. In the right fundus, there was a melanocytic lesion occupying the inferotemporal quadrant of the optic disk, extending to the adjacent choroid inferiorly; optic nerve edema, superotemporal retinal vein dilatation, and subretinal fluid under the macula and nasal half of the posterior pole were observed, and a subretinal choroidal neovascularization complex was observed adjacent to the superotemporal margin of the optic disk, confirmed by fluorescein angiography, surrounded by a dense subretinal hemorrhage. Optical coherence tomography showed retinal edema and detachment of neurosensory retina. The patient was treated with three consecutive doses on a monthly basis of intravitreal 1.25 mg/0.05 mL bevacizumab. Visual acuity recovered rapidly, and at 4 months after treatment, it was 20/20 and Jaeger 1, with complete resolution of macular edema and subretinal fluid and hemorrhage. After 3 years of follow-up, best-corrected visual acuity remained stable, macular area was normal, and there was no evident optic nerve edema, retinal vein caliber and aspect were normal, and there was no significant change of the tumor. Fluorescein angiography only evidenced late staining of choroidal neovascularization scar, and optical coherence tomography showed a normal macular anatomy. CONCLUSION: Intravitreal bevacizumab was effective in the treatment of choroidal neovascularization, optic nerve edema, venous dilatation, and local capillary telangiectasia, complicating an optic disk melanocytoma. Dove Medical Press 2015-03-06 /pmc/articles/PMC4358416/ /pubmed/25834382 http://dx.doi.org/10.2147/OPTH.S80152 Text en © 2015 Urrets-Zavalia et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Case Report Urrets-Zavalia, Julio A Crim, Nicolas Esposito, Evangelina Correa, Leandro Gonzalez-Castellanos, M Eugenia Martinez, Dana Bevacizumab for the treatment of a complicated posterior melanocytoma |
title | Bevacizumab for the treatment of a complicated posterior melanocytoma |
title_full | Bevacizumab for the treatment of a complicated posterior melanocytoma |
title_fullStr | Bevacizumab for the treatment of a complicated posterior melanocytoma |
title_full_unstemmed | Bevacizumab for the treatment of a complicated posterior melanocytoma |
title_short | Bevacizumab for the treatment of a complicated posterior melanocytoma |
title_sort | bevacizumab for the treatment of a complicated posterior melanocytoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358416/ https://www.ncbi.nlm.nih.gov/pubmed/25834382 http://dx.doi.org/10.2147/OPTH.S80152 |
work_keys_str_mv | AT urretszavaliajulioa bevacizumabforthetreatmentofacomplicatedposteriormelanocytoma AT crimnicolas bevacizumabforthetreatmentofacomplicatedposteriormelanocytoma AT espositoevangelina bevacizumabforthetreatmentofacomplicatedposteriormelanocytoma AT correaleandro bevacizumabforthetreatmentofacomplicatedposteriormelanocytoma AT gonzalezcastellanosmeugenia bevacizumabforthetreatmentofacomplicatedposteriormelanocytoma AT martinezdana bevacizumabforthetreatmentofacomplicatedposteriormelanocytoma |